Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients

  • Jonathan S. Zager (Creator)
  • Brian Gastman (Creator)
  • Sancy Leachman (Contributor)
  • Rene Gonzalez (Creator)
  • Martin D. Fleming (Creator)
  • Laura Ferris (Creator)
  • Jonhan Ho (Contributor)
  • Alexander Miller (Creator)
  • Robert W. Cook (Creator)
  • Kyle Covington (Creator)
  • Kristen Meldi-Plasseraud (Creator)
  • Brooke Middlebrook (Creator)
  • Lewis H. Kaminester (Creator)
  • Anthony J. Greisinger (Creator)
  • Sarah I. Estrada (Creator)
  • David Pariser (Creator)
  • Lee D. Cranmer (Creator)
  • Jane Messina (Creator)
  • John T. Vetto (Creator)
  • Jeffrey D Wayne (Creator)
  • Keith A. Delman (Creator)
  • David H. Lawson (Creator)
  • Gerami Pedram (Contributor)
  • Lewis H. Kaminester (Creator)



Abstract Background The heterogeneous behavior of patients with melanoma makes prognostication challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk was previously developed. This study evaluates the GEP’s prognostic accuracy in an independent cohort of cutaneous melanoma patients. Methods This multi-center study analyzed primary melanoma tumors from 523 patients, using the GEP to classify patients as Class 1 (low risk) and Class 2 (high risk). Molecular classification was correlated to clinical outcome and assessed along with AJCC v7 staging criteria. Primary endpoints were recurrence-free (RFS) and distant metastasis-free (DMFS) survival. Results The 5-year RFS rates for Class 1 and Class 2 were 88% and 52%, respectively, and DMFS rates were 93% versus 60%, respectively (P
Date made available2018

Cite this